FDAnews Drug Daily Bulletin

ATHENAGEN AND ZAPAQ TO MERGE

July 11, 2006
A A

Athenagen, Inc. and Zapaq, Inc., both privately held biopharmaceutical companies, said that they have signed a letter of intent to merge the two companies. The companies both have leading programs focused on neurological diseases, including several proprietary compounds targeting Alzheimer's disease. The merger is expected to be completed before the end of August.
Yahoo Finance